EI-tPA Gene Therapy

About Diorasis Therapeutics

Diorasis Therapeutics is an early-stage biotech focused on transforming glaucoma treatment through gene therapy. Its lead candidate is designed to upregulate an enzymatically inactive tissue plasminogen activator (EI-tPA) in the eye's trabecular meshwork, aiming to normalize outflow facility and provide a potentially lifelong reduction in intraocular pressure after a single administration. The company operates in a large market with significant unmet need, as current glaucoma treatments require chronic dosing and have compliance issues. Diorasis is at the preclinical stage, building a team with expertise in ophthalmology and gene therapy to advance its innovative platform.

Therapeutic Areas